Fluzone Trivalent Northern Hemisphere Injection, Suspension
Product Images NDC 49281-643

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Fluzone Trivalent Northern Hemisphere (NDC 49281-643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi Vaccines Us Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Principal Display Panel (5 mL Vial Label)
This is information about a 5 mL multi-dose vial of Influenza Vaccine called Fluzone®. It is indicated for individuals aged 6 months and older. The vaccine contains a preservative and should not be frozen, but stored between 2°C to 8°C (35°F to 46°F). The vial contains 5 mL of the vaccine and can be administered in doses of 0.25 mL or 0.5 mL for individuals aged 6 to 35 months and 0.5 mL for those 3 years and older. It is for intramuscular use, and the package insert should be referred to for detailed administration instructions. The vaccine is manufactured by Sanofi Pasteur Inc. and has a US Government License number #1725.*
FDA Label Image

Principal Display Panel (5 mL Vial Package)

Principal Display Panel (5 mL Vial Package)
This is a description of an influenza vaccine called Fluzone® intended for individuals 6 months of age and older. It is meant for intramuscular use and comes in a 5 mL multi-dose vial. The vaccine is designed for the 2023-2024 influenza season and contains specific strains of the flu virus. It is advised not to freeze the vaccine and to store it between 2°C to 8°C (35°F to 46°F). The vaccine is standardized according to USPHS requirements and is formulated to contain hemagglutinin representative of specific influenza virus strains.*
FDA Label Image

Principal Display Panel (0.5 mL Syringe Label)

Principal Display Panel (0.5 mL Syringe Label)
This is a description of an Influenza Vaccine called Fluzone intended for Intramuscular use. It is a single-dose product without preservatives, manufactured by Sanofi Pasteur Inc. The 2023-2024 formula is indicated and it comes in 0.5 mL volume. The National Drug Code (NDC) for this product is 49281-312-88.*
FDA Label Image

Principal Display Panel (0.5 mL Syringe Package)

Principal Display Panel (0.5 mL Syringe Package)
This text provides details about the Fluzone Reony Influenza Vaccine, suitable for intramuscular use for individuals 6 months of age and older. The vaccine is presented in 10 single-dose prefilled syringes, each containing 0.5 mL. It should be stored between 2°C to 8°C and should not be frozen. The vaccine is formulated to contain 45 micrograms hemagglutinin per 0.5 mL dose and is standardized according to USPHS requirements for the 2023-2024 influenza season. The text also mentions the specific prototype strains included in the vaccine and indicates that it contains no preservatives or natural rubber latex. The manufacturing information and trademark details are also provided within the text.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.